Page last updated: 2024-11-07

spironolactone and Lipodystrophy, Familial Partial

spironolactone has been researched along with Lipodystrophy, Familial Partial in 1 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Lipodystrophy, Familial Partial: Inherited conditions characterized by the partial loss of ADIPOSE TISSUE, either confined to the extremities with normal or increased fat deposits on the face, neck and trunk (type 1), or confined to the loss of SUBCUTANEOUS FAT from the limbs and trunk (type 2). Type 3 is associated with mutation in the gene encoding PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Schena, E1
Mattioli, E1
Peres, C1
Zanotti, L1
Morselli, P1
Iozzo, P1
Guzzardi, MA1
Bernardini, C1
Forni, M1
Nesci, S1
Caprio, M1
Cecchetti, C1
Pagotto, U1
Gabusi, E1
Cattini, L1
Lisignoli, G1
Blalock, W1
Gambineri, A1
Lattanzi, G1

Other Studies

1 other study available for spironolactone and Lipodystrophy, Familial Partial

ArticleYear
Mineralocorticoid Receptor Antagonism Prevents Type 2 Familial Partial Lipodystrophy Brown Adipocyte Dysfunction.
    Cells, 2023, Nov-07, Volume: 12, Issue:22

    Topics: Adipocytes, Brown; Adipose Tissue, Brown; HEK293 Cells; Humans; Lamin Type A; Lipodystrophy, Familia

2023